As the "portal" instrument for minimally invasive surgery, the global laparoscopic trocar market is experiencing robust and structural growth alongside the widespread adoption of minimally invasive surgery (MIS). According to industry research, the global market size of disposable laparoscopic trocars reached approximately 12.44 billion RMB in 2024, and is projected to expand at a compound annual growth rate (CAGR) of 11.6%, approaching nearly 26.68 billion RMB by 2031. Meanwhile, the reusable trocar market maintains steady growth, valued at around 536 million USD in 2024 and expected to reach 866 million USD by 2032. Driven by multiple growth factors, the market also exhibits distinct characteristics of regional divergence.

Core Growth Drivers: The Dual Momentum of Clinical Demand and Technological Penetration

The fundamental market driver stems from the remarkable advantages of minimally invasive surgery over traditional open surgery: smaller trauma, faster postoperative recovery, lower infection risk, and better cosmetic scar outcomes. It has rapidly become the standard surgical approach in general surgery (such as cholecystectomy and hernia repair), gynecology, urology and other disciplines. The rising global prevalence of chronic diseases such as obesity and gastrointestinal disorders has further broadened the indications for laparoscopic procedures, directly boosting demand for core consumables including trocars.

By product type, disposable trocars serve as the primary contributor to market growth, benefiting from ready-to-use availability, guaranteed sterility, no need for cleaning and disinfection, elimination of cross-infection risks, and saved surgical preparation time. However, their higher single-use cost and increased medical waste disposal pressure pose challenges to market penetration, especially in budget-constrained emerging markets. Reusable trocars still maintain steady demand among medical institutions prioritizing sustainable development, thanks to their long-term cost-effectiveness and eco-friendly attributes.

Regional Market Landscape: A Dual Narrative of Mature and Emerging Markets

The global market demonstrates highly concentrated regional features. North America (particularly the United States) and Europe represent the largest and most mature markets, accounting for the majority of global revenue share. These regions feature well-developed healthcare systems, high adoption rates of advanced minimally invasive technologies, strong affordability, and comprehensive regulatory frameworks including the U.S. FDA and EU MDR, leading product innovation and high-end clinical demand. The U.S. market is especially concentrated, with two industry giants, Ethicon (Johnson & Johnson) and Medtronic, collectively holding around 50% of the market share.

The Asia-Pacific region, especially China, stands out as the fastest-growing growth engine. Driven by rapid improvements in medical infrastructure, expanded medical insurance coverage, and rising patient awareness of minimally invasive treatment, China's market growth rate is significantly higher than the global average. Local manufacturers such as Kangji Medical and Foshan Special Medical Catheter are rising rapidly, continuously capturing market share from international brands through cost-performance advantages and innovations tailored to local clinical needs. In addition, emerging markets across Southeast Asia and Latin America show substantial growth potential, yet their expansion is constrained by limited medical budgets and underdeveloped infrastructure, with higher sensitivity to product costs.

Future Outlook: Value-Oriented Development and Personalized Innovation

Going forward, competition in the global laparoscopic trocar market will move beyond the simple dichotomy of disposable versus reusable products, shifting toward deeper value-based healthcare. This requires products to not only fulfill basic functional needs, but also deliver unique value in enhancing surgical safety (such as visualized puncture to reduce trauma risk), optimizing operational efficiency (e.g., variable-diameter design to minimize instrument replacement), improving patient prognosis (reducing complications), and controlling overall treatment costs amid ongoing DRG/DIP payment reforms. Manufacturers capable of delivering integrated solutions rather than standalone products will gain a more advantageous position in future global competition.